| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
|
N Engl J Med
|
1997
|
3.03
|
|
2
|
Primary lymphoma of the spleen. Clinical features and outcome after splenectomy.
|
Cancer
|
1988
|
1.32
|
|
3
|
Primary lymphoma of the liver.
|
Cancer
|
1988
|
1.24
|
|
4
|
The non-Hodgkin's lymphomas. I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969.
|
Cancer
|
1983
|
1.18
|
|
5
|
AIDS-related lymphoid neoplasia. The Memorial Hospital experience.
|
Cancer
|
1988
|
1.14
|
|
6
|
Hematologic aspects oa alcoholism.
|
Semin Hematol
|
1973
|
1.14
|
|
7
|
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.
|
Bone Marrow Transplant
|
1999
|
1.08
|
|
8
|
Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion.
|
Cancer
|
1983
|
1.03
|
|
9
|
Angioimmunoblastic lymphadenopathy: clinical spectrum of disease.
|
Cancer
|
1981
|
1.02
|
|
10
|
The acute monocytic leukemias: multidisciplinary studies in 45 patients.
|
Medicine (Baltimore)
|
1980
|
0.99
|
|
11
|
Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive man.
|
Cancer
|
1987
|
0.99
|
|
12
|
Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease.
|
Chest
|
2000
|
0.93
|
|
13
|
Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
|
Cancer
|
1993
|
0.93
|
|
14
|
Recent results of multimodal therapy of gastric lymphoma.
|
Cancer
|
1986
|
0.92
|
|
15
|
CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease.
|
Blood
|
1996
|
0.92
|
|
16
|
Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.
|
J Clin Oncol
|
1996
|
0.91
|
|
17
|
Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.
|
J Clin Oncol
|
1993
|
0.88
|
|
18
|
Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.
|
Am J Med
|
1988
|
0.87
|
|
19
|
Lymphoma and other HIV-associated malignancies.
|
J Am Acad Dermatol
|
1990
|
0.87
|
|
20
|
CT of primary lymphoma of the liver.
|
AJR Am J Roentgenol
|
1989
|
0.87
|
|
21
|
Cicatricial ectropion secondary to 5-fluorouracil therapy.
|
Med Pediatr Oncol
|
1977
|
0.86
|
|
22
|
Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols.
|
J Clin Oncol
|
1983
|
0.85
|
|
23
|
Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations.
|
J Clin Oncol
|
1991
|
0.84
|
|
24
|
Hodgkin's disease presenting with rectal symptoms in a homosexual male. A case report and review of the literature.
|
Cancer Invest
|
1984
|
0.83
|
|
25
|
Osteonecrosis in patients with malignant lymphoma: a review of twenty-five cases.
|
Cancer
|
1981
|
0.83
|
|
26
|
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
|
Ann Oncol
|
2007
|
0.81
|
|
27
|
Semen cryopreservation and artificial insemination for Hodgkin's disease.
|
J Clin Oncol
|
1987
|
0.81
|
|
28
|
Concanavalin A-induced suppressor cell activity in Hodgkin's disease.
|
Clin Immunol Immunopathol
|
1980
|
0.81
|
|
29
|
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.
|
J Clin Oncol
|
1990
|
0.81
|
|
30
|
Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.
|
Cancer
|
1982
|
0.81
|
|
31
|
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy.
|
Leuk Lymphoma
|
2000
|
0.81
|
|
32
|
Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen of MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease.
|
Cancer Treat Rep
|
1982
|
0.80
|
|
33
|
Plasmacytoma and the acquired immunodeficiency syndrome.
|
Ann Intern Med
|
1983
|
0.80
|
|
34
|
Long-term follow-up of cardiac function in patients with Hodgkin's disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin.
|
Cancer Treat Rep
|
1986
|
0.80
|
|
35
|
Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
|
J Clin Oncol
|
1990
|
0.79
|
|
36
|
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
|
Ann Oncol
|
2009
|
0.79
|
|
37
|
Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma.
|
J Nucl Med
|
1992
|
0.79
|
|
38
|
Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typing.
|
Blood
|
1980
|
0.78
|
|
39
|
Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.
|
Cancer Treat Rep
|
1983
|
0.78
|
|
40
|
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
|
J Clin Oncol
|
1993
|
0.77
|
|
41
|
Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities.
|
Am J Med
|
1986
|
0.77
|
|
42
|
Strategies in the treatment of Hodgkin's disease.
|
Semin Oncol
|
1986
|
0.76
|
|
43
|
Comparison of survival in cerebral palsy between countries.
|
Dev Med Child Neurol
|
2001
|
0.76
|
|
44
|
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
|
Ann Oncol
|
2004
|
0.76
|
|
45
|
Osteonecrosis in patients with malignant lymphoma. A review of 31 cases.
|
Cancer
|
1986
|
0.76
|
|
46
|
Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: an analysis of prognostic factors in two chemotherapy trials and the literature.
|
Cancer Treat Rep
|
1981
|
0.75
|
|
47
|
The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up report.
|
Cancer
|
1980
|
0.75
|
|
48
|
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.
|
Invest New Drugs
|
1991
|
0.75
|
|
49
|
Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy.
|
Cancer
|
1993
|
0.75
|
|
50
|
NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma.
|
Cancer
|
1984
|
0.75
|
|
51
|
Treatment of advanced Hodgkin's disease with chemotherapy and irradiation. Controlled trial of two versus three alternating, potentially non-cross-resistant drug combinations.
|
Am J Med
|
1984
|
0.75
|
|
52
|
Atypical lymphoma with prolonged systemic remission after splenectomy. Description of three cases.
|
Am J Med
|
1974
|
0.75
|
|
53
|
Effectiveness of methyl-GAG (methylglyoxal-bis[guanylhydrazone]) in patients with advanced malignant lymphoma.
|
Blood
|
1981
|
0.75
|
|
54
|
Localized non-Hodgkin's lymphoma of the breast.
|
Cancer
|
1987
|
0.75
|
|
55
|
Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
|
Cancer Clin Trials
|
1981
|
0.75
|
|
56
|
Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
|
Cancer Treat Rep
|
1981
|
0.75
|
|
57
|
Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26).
|
Cancer Treat Rep
|
1982
|
0.75
|
|
58
|
The treatment of advanced Hodgkin's disease at Memorial Hospital.
|
Clin Bull
|
1980
|
0.75
|
|
59
|
Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatment.
|
Am J Med
|
1987
|
0.75
|
|
60
|
Evaluation of malignant lymphomas using three classifications and the working formulation. 482 cases with median follow-up of 11.9 years.
|
Am J Med
|
1986
|
0.75
|
|
61
|
The treatment of advanced hodgkin's disease.
|
Blut
|
1981
|
0.75
|
|
62
|
The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis.
|
Blood
|
1979
|
0.75
|
|
63
|
Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
|
Cancer Chemother Pharmacol
|
1983
|
0.75
|
|
64
|
Value of splenectomy in non-Hodgkin's lymphoma.
|
Cancer
|
1985
|
0.75
|